Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)

被引：0
|
作者：
Kapoun, A. [1 ]
O'Reilly, E. [2 ]
Cohn, A. [3 ]
Bendell, J. C. [4 ]
Smith, L. [5 ]
Strickler, J. H. [6 ]
Gluck, W. [7 ]
Liu, Y. W. [1 ]
Wallace, B. [1 ]
Tam, R. [1 ]
Cancilla, B. [1 ]
Brunner, A. [1 ]
Hill, D. [1 ]
Zhou, L. [1 ]
Dupont, J. [1 ]
Zhang, C. [1 ]
Wang, M. [1 ]
机构：
[1] OncoMed Pharmaceut, Davis, CA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] Sarah Canon Res Inst, Nashville, TN USA
[5] START, San Antonio, TX USA
[6] Duke Univ, Durham, NC USA
[7] Greenville Hosp Syst, Greenville, SC USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70591-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
465
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [21] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (PI) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial
    Ko, Andrew H.
    Murphy, Patrick Brian
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Francisco Antonio
    Womack, Mark Sanders
    Xiong, Henry Q.
    Waterhouse, David Michael
    Tempero, Margaret A.
    Guo, Shuangli
    Lane, Cassie Michelle
    Earwood, Christopher
    DeBusk, Laura M.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
    Ko, Andrew H.
    Murphy, Patrick B.
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Frank A.
    Womack, Mark S.
    Xiong, Henry Q.
    Waterhouse, David M.
    Tempero, Margaret A.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial
    Fernandez, A.
    Salgado, M.
    Garcia, A.
    Buxo, E.
    Vera, R.
    Adeva, J.
    Jimenez, P.
    Quintero, G.
    Llorca, C.
    Canabate, M.
    Lopez, L. J.
    Munoz, A.
    Ramirez, P.
    Gonzalez, P.
    Lopez, C.
    Reboredo, M.
    Gallardo, E.
    Sanchez, M.
    Gallego, J.
    Guillen, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
    Weekes, C.
    Berlin, J.
    Lenz, H-J.
    O'Neil, B.
    Messersmith, W.
    Cohen, S.
    Dendinger, C.
    Shahda, S.
    Kapoun, A.
    Zhang, C.
    Jenner, R.
    Cattaruzza, F.
    Xu, L.
    Dupont, J.
    Brachmann, R.
    Uttamsingh, S.
    Farooki, A.
    Dotan, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer
    Davis, S. Lindsey
    Cardin, Dana Backlund
    Shahda, Safi
    Lenz, Heinz-Josef
    Dotan, Efrat
    O'Neil, Bert
    Kapoun, Ann M.
    Stagg, Robert J.
    Berlin, Jordan
    Messersmith, Wells A.
    Cohen, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
    Moore, Malcolm J.
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hon, Jeremy K.
    Biakhov, Mikhail Yu
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin D.
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Romano, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
    Steven J. Cohen
    Bert H. O’Neil
    Jordan Berlin
    Patricia Ames
    Marti McKinley
    Julie Horan
    Patricia M. Catalano
    Angela Davies
    Colin D. Weekes
    Lawrence Leichman
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 693 - 701
  • [30] A phase 1b/2 trial of SHR-1701 in combination with gemcitabine and nab-paclitaxel in patients with untreated locally advanced or metastatic pancreatic cancer.
    Zhou, Jun
    Yu, Xianjun
    Li, Zhihua
    Zhou, Yuhong
    Li, Jialin
    Xue, Ran
    Xia, Ye
    Han, Hongxia
    Wu, Yiwen
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16264 - E16264
12345